Member Info for MoreThanMe

"Chinese partner estimates potential sales of 1.0m Food Detective tests in calendar 2023 –subject to NMPA approval for self-test."

Remember that food intolerance has global coverage and brand reach in over 75 countries and isn't limited to China only, I remember that Collin was talking about America in one of the presentations.

Investor Meets Company Food Intolerance slide: https://imgur.com/a/Qks34WT

The company has just gone from strength to strength. The company has so much going on with covid lfts and yet continue to deliver key milestones on both their cd4 hiv and food intolerance businesses. Cream of the crop here.

Fantastic news on food intolerance self test approval in China, the company has worked tremendously hard for this, well done Collin and team.

With self test in China approved, more of the companies market cap will be underlined by non covid core business revenues. Fantastic news.

78p is the resistance to break through, after that there isn't much resistance until 90p and then 108p.

Volume increasing here, 130k traded in the last 5 minutes alone. Everyone knows this has been held down by L&G selling and is a coiled spring right now.

There was no way we were going to stay in the 70s for long, this was way too oversold at this level. Well done to any new holders that have entered here. Excellent risk to reward from here.

Fantastic volume here, when L&G are finished selling, Omega will rise fast.

Collin's "understated honest approach" is a massive bonus to investors here, it has kept the stock at a reasonable valuation allowing for attractive entry for newcomers, which is essential for the stock is to continuously grow over the long term. Look at the GDR graph, I sold my stake there at 110p before the exponential rise to 300p and initially was kicking myself for it, but ever since then, the stock has struggled to gain traction and re-test their prior high. Slow and steady monthly growth in SP and capacity is what we want here, not short term spikes that screw over the retail investor.

For investors looking to hedge their portfolio from Covid, it doesn’t get much better than Omega. For an investor heavily invested in FTSE / SP500 indexes, a 5%+ investment of their portfolio in Omega, would offer significant downside protection. The longer covid lasts, the lower the FTSE will drop, but the more favourably the market will value Omega in terms of P/E ratio when the company reaches its goal manufacturing capacity.

Investors looking to enter the stock now couldn’t choose a better time, the company has been significantly de-risked over the last 6 months and is fully funded to increase LFT manufacturing capacity to 500k / week by Decemeber and 2m+ / week by April. Regarding Covid testing; the company has a diversified portfolio of LFTs with the UK-RTC home antibody test, their self-branded Visitect triple antibody LFT as well as an antigen LFT in the pipeline that should be CE marked by Mologic this month, with tech-transfer to quickly follow.

With significant divisions within food intolerance testing and CD4 (HIV) testing, the company has significant experience, reputation and worldwide presence in the testing and in particular lateral flow testing sector. These non-covid divisions underpin significant value and offer fantastic additional growth of the company, highlighting that Omega is not only a covid play.

On top of all of the above, on a technical basis, the stock is at the most oversold point since March as shown by the 4 hour RSI. The risk to reward here couldn’t be more attractive and Omega is not going to stay in the 70p range for long next week.

4 hour RSI oversold chart: https://imgur.com/a/qi75u8k

If you are looking for an entry into the stock, I don't think it gets any better than right now. Fundamentally, the company has been hugely de-risked, has a clear and fully funded route to 2m+ LFT tests / week, an excellent portfolio of tests as well as an antigen LFT potentially coming before Christmas.

But if that alone is not enough, on a technical basis, the stock has not been more oversold than it is now, since the end of March as indicated by the RSI on a 4 hour chart. Off that low in March the stock increased by over 1000% in a little over a month. We might not see a move quite that explosive, but it highlights, just how undervalued and oversold we are, offering a highly attractive entry point for both existing and new investors.

Link to chart: https://imgur.com/a/qi75u8k

The market is indiscriminate when it sells off, even gold which is supposed to be a safe heaven sells off during these liquidity events. Don't judge companies by their price movement during wide market sell off, but instead judge them by their ability to bounce back and outperform the market when the sell off is over. I have watched this stock go from 20p to 91p to 33p and back up to 110p+, back down to 70p. It is all irrelevant price movement, what is important is the build up of capacity and our testing portfolio . I haven't traded Omega once, the potential on offer with Omega is too large to risk being out of the stock, when the market finally wakes up. I can't think of any industry that is going to see the exponential demand growth than Omega will see in the next few years. GLA

I think Christmas will be a pivotal moment for lateral flow testing to gain mainstream traction. When visiting family (particularly vulnerable family members), the general public will start to think more about testing as a confirmation that they don’t have Covid, as opposed to a verification that they do have it. Lab testing will never be able to service the demand for symptomless testing, hence why the government has always discouraged people from getting a test unless they are showing symptoms. Lateral flow testing is one of the only solutions for symptomless testing, with its low cost, rapid results and portability.

Lab testing has been sufficient so far to meet a good proportion of the demand of people with symptoms, however as flu season gets into full swing, the logistics, slow turn around time and price is all going to bite as the sheer scale of demand increases. Lateral flow testing will be the second generation of tests that will solve all of these problems for testing of people with symptoms and without.

I was extremely fortunate to get a favourable entry point earlier in the year, but only because of institutional investors selling down their stakes. The likes of Legal & General, Octopus, Oryx and Richard Sneller selling aggressively at that time allowed me to enter the stock at a much lower price than I was expecting to pay following my research into the company. These II have all invested at 15-25p, so they have made impressive returns and it is unsurprising that they have taken profit from their investment.

The same thing is happening now, their selling is offering another fantastic entry point. On a risk to return basis, buying in the 70p range is far more favourable than when I initially brought in because of the de-risking that has occurred, how well Collin has diversified Omega's portfolio of tests, the cash on hand and scale of capacity.

It looks like today Omega was caught in a big market sell off, for people that are holding with their eye on the prize, it is a small blip along the journey. 500k LFT / week by the end of the year with plans of expansion in the new year to 2.5m / week. Mologic LFT maybe arriving sooner than expected. Nothing has changed here, with down days Omega will follow the market movements, but on average will dramatically outperform the market in the next few years. Look at the performance this year so far and there is a lot more ramping up of production to look forward to.

Reading about this antigen test offering from Boots, it costs £120 and is limited to symptomless people only. It states that if you have covid symptoms, do not get a test from Boots and self isolate following government test.

So the only use for this test I can see is to confirm you don't have covid prior to seeing a vulnerable family member/friend.

I have posted this 4 times over the last 2 months, but I guess it is required again:

From the Investor meets company presentation link to a screenshot of the slide below showcasing the funds raised in June and what the funds will/are being used for:

- £1.1m | COVID-19 –ELISA Testing: 275k tests per week to 1m tests per week
- £3.0m | COVID-19 –LFT: 100k tests per week to 500k tests per week (£1.1m) extended to 1.0m tests per week (£1.9m)
- £0.4m | VISITECT® CD4Margin Improvement
- £2.7m | Expand Lateral Flow Product Portfolio
- £1.0m | Repayment of Overdraft Facility
- £2.3m | Working Capital estimate
-----------
- £10.5m | Total

Link: https://imgur.com/a/nHmLEdz

A perfect example of this is the consolidation of Novacyt over the summer months, trading within the 200-350p range, a lot of traders/investors did the research, understood the value in Novacyt and the potential, but lacked the patience to sit on their hands and watch their investment come to fruition. With investing, not only do you have to get the investment right, but you need to hold your shares long enough for the market to recognize the same value that you believe the company has.

And that is where we are at with Omega, the company is going from strength to strength, expanding capacity, bringing their portfolio of tests to the market and getting government orders. We don't need MHRA approvals here or design freeze, we only need patience.

Strong message from Boris today, it is a shame the market didn't have more time to digest Boris's words before the close. His words are another puzzle piece, explaining the UK industrial ramp up of testing cassettes, packaging and lateral flow testing manufacturing capacity. Collin needs to increase the LFT capacity to 2.5m / week ASAP, the country needs it.

quote: "Work had been started to manufacture the tests domestically, to ensure the UK can produce millions of the tests."

link: https://www.mirror.co.uk/news/politics/boris-johnson-says-new-15-22858473

4 hourly chart is looking very nice now with similarities to the previous breakouts we have had at the start and end of September. GLA

chart: https://imgur.com/a/oF7Hxnl

Excellent find hanskrankl, there are so many piece of this puzzle that lead to the exact same conclusion that there will be insatilbe demand for home testing lateral flow tests. All of these manufaturers ramping up production of their individual component will not be doing this at risk without a guaranteed demand for their output.